Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$9.81 USD
-0.04 (-0.41%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $9.82 +0.01 (0.10%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth C Momentum C VGM
Income Statements
Fiscal Year end for Amicus Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 399 | 329 | 306 | 261 | 182 |
Cost Of Goods | 37 | 39 | 34 | 31 | 22 |
Gross Profit | 362 | 291 | 271 | 230 | 160 |
Selling & Adminstrative & Depr. & Amort Expenses | 439 | 503 | 477 | 477 | 464 |
Income After Depreciation & Amortization | -77 | -212 | -206 | -247 | -304 |
Non-Operating Income | -23 | 7 | -3 | -5 | -33 |
Interest Expense | 50 | 37 | 32 | 22 | 19 |
Pretax Income | -150 | -242 | -242 | -274 | -356 |
Income Taxes | 1 | -5 | 9 | 3 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -152 | -237 | -250 | -277 | -356 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -152 | -237 | -250 | -277 | -356 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -67 | -204 | -198 | -236 | -297 |
Depreciation & Amortization (Cash Flow) | 10 | 8 | 9 | 11 | 7 |
Income After Depreciation & Amortization | -77 | -212 | -206 | -247 | -304 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 295.17 | 289.06 | 271.42 | 258.87 | 240.42 |
Diluted EPS Before Non-Recurring Items | -0.51 | -0.82 | -0.92 | -1.04 | -1.31 |
Diluted Net EPS (GAAP) | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 |
Fiscal Year end for Amicus Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 110.40 | 115.08 | 103.50 | 94.50 | 86.27 |
Cost Of Goods | 13.57 | 11.32 | 9.95 | 9.11 | 6.94 |
Gross Profit | 96.84 | 103.76 | 93.56 | 85.39 | 79.33 |
SG&A, R&D, and Dept/Amort Expenses | 124.55 | 107.45 | 110.58 | 104.25 | 116.97 |
Income After SG&A, R&D, and Dept/Amort Expenses | -27.71 | -3.69 | -17.02 | -18.86 | -37.64 |
Non-Operating Income | -3.43 | -15.14 | 5.30 | -9.17 | -3.74 |
Interest Expense | 12.44 | 12.83 | 12.99 | 12.49 | 11.84 |
Pretax Income | -43.58 | -31.66 | -24.71 | -40.52 | -53.22 |
Income Taxes | 4.84 | 2.18 | -3.13 | 2.72 | -0.29 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -48.42 | -33.84 | -21.58 | -43.23 | -52.93 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -48.42 | -33.84 | -21.58 | -43.23 | -52.93 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 302.90 | 295.17 | 295.76 | 292.80 | 291.34 |
Diluted EPS Before Non-Recurring Items | -0.02 | -0.11 | -0.07 | -0.15 | -0.18 |
Diluted Net EPS (GAAP) | -0.16 | -0.11 | -0.07 | -0.15 | -0.18 |